H. Lundbeck A/S

Company snapshot

H. Lundbeck A/S is a pharma organization headquartered in Valby, CN. Primary therapeutic focus areas include Migraine, Narcolepsy, Schizophrenia, Multiple System Atrophy, Chronic Migrane, Migrane, Medication Overuse Headache. NovaPharmaNews links 17 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (7), phase 1 (5), phase 2 (4).

• 17 active pipeline program(s) linked via ClinicalTrials.gov.
• 17 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for H. Lundbeck A/S. Not investment advice.

• Peer + 0 momentum

  Jazz Pharmaceuticals Ireland

  TA overlap score 40

• Peer + 0 momentum

  NEUROCRINE BIOSCIENCES

  TA overlap score 35.8

• Peer + 0 momentum

  Addex Therapeutics

  TA overlap score 31.2

• Peer + 0 momentum

  SUPERNUS PHARMACEUTICALS

  TA overlap score 31

• Peer + 0 momentum

  Acadia Pharmaceuticals

  TA overlap score 26.4

• Peer + 0 momentum

  Axsome Therapeutics

  TA overlap score 25.6

• Peer + 0 momentum

  Amneal Pharma Europe

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for H. Lundbeck A/S.

1. Jun 8, 2026 Clinical update

   21117A — Phase 1

2. Jun 8, 2026 Clinical update

   20653A — Phase 1

3. Jun 8, 2026 Clinical update

   19356A — Phase 3

4. Jun 8, 2026 Clinical update

   20453A — Phase 1

5. Jun 8, 2026 Clinical update

   20433A — Phase 2

View all clinical trial activity →

• What is H. Lundbeck A/S?

  H. Lundbeck A/S is a pharma organization headquartered in Valby, CN. Primary therapeutic focus areas include Migraine, Narcolepsy, Schizophrenia, Multiple System Atrophy, Chronic Migrane, Migrane, Medication Overuse Headache. NovaPharmaNews links 17 clinical program(s), 0 drug pr

• Is H. Lundbeck A/S publicly traded?

  H. Lundbeck A/S appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does H. Lundbeck A/S develop or market?

  We link 14 drug profile(s) where H. Lundbeck A/S is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/h-lundbeck-a-s#company-drugs.

• What are the latest developments for H. Lundbeck A/S?

  In the last 12 months our linked public records show 17 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does H. Lundbeck A/S focus on?

  H. Lundbeck A/S focuses on Migraine, Narcolepsy, Schizophrenia based on our analysis of their pipeline programs and drug development activities.